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Abstract 
Continuous Manufacturing has enabled the potential for significant step changes within 
the Pharmaceutical industry. However, adoption rates remain in the range of 5%. This 
research examines the challenges and implications of the shift from ‘batch’ to 
‘continuous’ processing in terms of e.g. product variety and supply network design. 
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Introduction 
On-going new technology development in the area of ‘Continuous Manufacturing’ (CM) 
has enabled potential for significant step changes within the Pharmaceutical sector e.g. 
shifting from traditional ‘batch’ to ‘continuous’ processing has implications for (a) 
product variety, consistency and functionality (b) energy and resource efficiency (c) 
inventory and customization options and (d) overall industry structure. While other 
industries, such as oil, gas, petrochemicals, polymers, and food currently operate in CM 
mode; extensive use of CM is still relatively new to the pharmaceutical industry where 
the current adoption rate of continuous processing is approximately 5 %. Despite the fact 
that 50% of reactions in pharma could benefit from a continuous process based on e.g. 
micro-reactor technology, the industry still dominated by batch processes and it is 
estimated that rejected batches, rework and investigations can equate to as much as 25% 
of pharmaceutical company revenues (Alinaghian et al. 2012, Arnum and Whitworth, 
2011). 
The key difference between batch and continuous processing is that in batch 
mode, the process is in a dynamic state from the beginning of the reaction until the end. 
Depending on the process the end point is predetermined so that when that point is 
reached, the process is stopped, and the unit operation is completed. A continuous 
process, however, must undergo an initial start-up phase before reaching a ‘steady state’ 
(Rios 2007). Batch process manufacturing is segmented into many individual steps that 
are often performed at separate facilities, thereby, requiring frequent interruptions in 
production activities. In this manufacturing model, specific quantities of a drug are 
produced to fill an order and quality is assessed through sampling, using analytical test 
and measurement. If the quality standards are not met, the entire batch is rejected and sent 
back for reprocessing. 
On the other hand, in a continuous manufacturing model, raw materials are put 
2 
into the automated system that is capable of carrying out complex chemical tests 
according to the predetermined quality parameters. These quality checks occur throughout 
the manufacturing process and most importantly without interruption. Rejected products 
may be handled through recycling loops, enabling the reuse of some or all component 
parts (Schaber et al. 2011). 
Batch process manufacturing, the current industry standard, offers several 
benefits and suffers several drawbacks. On the positive side, batch processing assures 
quality as a batch may be controlled, and thus, accepted or rejected (Leuenberger, 2001). 
Moreover, when compared with continuous processing, batch process manufacturing 
provides higher flexibility in producing multiple products in a single plant through the 
sharing of process equipment (Behr, 2004; Gorsek and Galvic, 1997). On the negative 
side, batch production presents many disadvantages including long throughput times 
from start to finish (Calabrese and Pissavini, 2011), large raw material and intermediate 
inventories (Gorsek and Galvic, 1997; Kim and Lee, 1993), extensive validation and 
scale-up activities with products often of lower and/or inconsistent quality (batch-to-
batch variation). By-products lead to undesirable side effects; products have been 
rejected at the clinical trials stage because of concerns over purity. 
Continuous manufacturing is gaining ever-increasing attention within the 
pharmaceutical industry because of the expanding profitability gap experienced by most 
pharmaceutical companies (Gerogiorgis and Barton, 2009). Today, it is becoming more 
difficult for pharmaceutical companies to meet profit expectation, due to increasing 
research and development (R&D) operating costs and competition from generic 
manufactures. A review of the fine and commodity chemical industries has demonstrated 
that continuous manufacturing could offer both operating expenditure (OpEx) and capital 
expenditure (CapEx) savings for the pharmaceutical industry. Furthermore, labor for 
transporting material between batch units, quality assurance/quality control (QA/QC), and 
in process inventory can all be significantly reduced in continuous manufacturing. 
According to the Trout research group, the increasing interest in continuous 
manufacturing can be attributed to a combination of three factors of the beginning of 
more flexible regulatory approaches, increasing cost pressure and increasing quality and 
controls specifications of pharmaceuticals (Schaber et al. 2011). 
Hence, the pharmaceutical industry and the regulatory bodies are now actively 
encouraging the development and implementation of innovative pharmaceutical 
manufacturing systems e.g. a recent study into the future of High Value Manufacturing 
(HVM) in the UK, commissioned by the Technology Strategy Board, was published in 
February 2012 (TSB 2012). One of the HVM study recommendations was that particular 
manufacturing sectors should be explored in greater depth and this report presents the 
findings from studies of the pharmaceutical and biopharmaceutical sectors. Workshops 
were held for each sector attended by representatives from industry, government bodies 
and the research community. The aims were to: 
 identify the needs and capability gaps to achieving innovation in manufacturing in 
each sector through to 2025 
 determine priority actions to meet these needs and build capability to enable 
innovation in manufacturing in each sector over this time scale 
 better define the HVM landscape with additional data from the Life Sciences 
sector. 
Regulatory  Social Process Technology  
Economic 
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Strategic road mapping techniques were used to help participants explore the 
pharma sector’s key trends and drivers; the novel products, processes and services which 
could be developed in the future; any technologies and capabilities required to support 
these opportunities; and the enabling factors that would help the sector respond 
successfully. The list of potential new products, processes and services was prioritized to 
identify key areas where it was thought the most valuable opportunities for innovation 
exist. A ‘case for action’ was developed to justify further work in each area, outlining the 
potential benefits, critical gaps and steps required (TSB 2012). 
Research Approach 
This specific research paper looks to initially explore and address (a) the operations and 
supply chain management challenges associated with CM and (b) relevant findings from 
the TSB report, through the following approaches: 
 Exploration of the barriers and enablers for CM adoption within pharma 
 Developing an emerging Value Chain Road mapping approach: exploring product-
process archetypes and the implications new product and technology roadmaps, 
within CM and Pharma, may have on the future value chain 
 Development of an emerging analysis framework; to enable end-to-end supply 
chain assessment and support overall business impact analysis in making a shift to 
CM where applicable (currently at conceptual level). 
Figure 1. Barriers to CM adoption in Pharma (adapted from Alinaghian et al. 2012)  
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CM: Barriers and Enablers 
Previous work has summarized the existing barriers and enablers to the adoption of the 
continuous manufacturing model within the Pharma industry (Alinaghian et al. 2012), 
which benefited from collective discussions and one-to-one interviews with the 
organizations currently going through the transition from batch to CM and encountering 
such challenges. The key findings are summarized in figures 1 and 2. 
This exploratory qualitative research included two main phases of systematic 
literature review and exploratory case studies comprising of semi-structured interviews, 
theory building and concept development workshops involving industry practitioners, 
technologists and process engineers. The study revealed that despite recent efforts to 
quantify economic benefits of continuous manufacturing, the overall business impact of 
continuous manufacturing lacks an end-to-end supply chain assessment (Alinaghian et al. 
2012). 
 
Cost 
 Capital investment 
 Continuous manufacturing allows the use of smaller production facilities with lower capital cost, with 
a reduced overall plant footprint. 
 Operating Costs 
 Less labour required to operate the processes 
 Continuous process is capable of increasing asset utilisation 
 Lower catalyst and solvent use 
 Minimize total reaction time through better temperature control 
 Effective running and scaleAup of exothermic reactions without special equipment/ additional 
precautions 
 Inventory 
 Continuous manufacturing has potential for reducing inventory cost (Less WIP inventory, 
Reduced material handling and transport, Continuous flow of material) 
 
Quality 
 Improves process control 
 CM system is considered to be integration of quality and compliance system. 
 Product yield and quality will be better in CM compared to batch process. – Higher purity 
 Less product reject 
 The continuous manufacturing enables monitoring of drug quality on a continuous basis rather 
than through postAproduction, batchAbased testing. 
Delivery  Continuous process enhances process reliability 
 
Speed 
 Strategic 
 Continuous manufacturing accelerates the introduction of new drugs through efficient 
production processes 
 Continuous process reduces the time to market 
 Continuous process is capable of reducing the cycle time 
 Operational 
 Continuous process is highly capable of minimizing total reaction time through better 
temperature control compared to batch process. 
 No Scale2up development is necessary in continuous manufacturing, as the early 
clinical batches are produced using exactly the same equipment as the large production 
batches. 
Flexibility 
 Process flexibility 
 Different degree of flexibility to change the product mix (product flexibility) 
 Different degree of flexibility to react to changes in demand (volume flexibility)  
Sustainability • Continuous manufacturing minimizes waste, energy consumption and raw material use.  
 Solvent can be recycling more effectively in continuous process compared to batch process.  
Figure 2. Enablers of CM (adapted from Alinaghian et al. 2012) 
5 
Some high level findings from this literature review show that evidence exists for: 
 CM delivering financial benefits (mainly for single-purpose plant). 
 A need to better quantify the economic benefits of CM (given that the overall 
business impact lacks an end-to-end supply chain assessment) 
 While most opportunities lie in supply chain design and configuration, existing 
studies are largely focused on production and plant level. 
Emerging Value Chain road mapping approach 
Outputs from previous work (Alinaghian et al. 2012) also suggests that many of the 
critical issues are not simply about a ‘batch to continuous shift’ but more about the 
alternative product-process supply network options and value chain implications of e.g. 
 Product variety, consistency and functionality 
 Energy and resource efficiency (e.g. capital investment, solvent use, number of 
process steps) 
 Inventory, minimum ‘lot’ size, customisation options etc. 
To this effect, this research is currently exploring the viability of attractive product-
process archetypes which may exist at required scale [CM-batch mix, intermediates (e.g. 
batch unstable), substance dose form), plug-and-play instant/rapid changeover process 
technologies, viable product-process network configurations which may exist that meet 
product portfolios]. 
To support capture of the associated alternative product-process supply network 
options and value chain implications for such ‘attractive product-process archetypes’, an 
emerging value chain road mapping approach has been developed which builds on 
techniques in mapping supply chain configurations (Srai and Gregory, 2008) across the 
manufacturing value chain. In these studies, the supply network configuration has been 
defined as “that particular arrangement or permutation, of the supply network’s key 
elements including, the “network structure” of the various operations within the supply 
network and their integrating mechanisms, the flow of materials and information between 
and within key “unit operations” the “role, inter-relationships, and governance” between 
key network partners, and the “value structure” of the product or service delivered”. In 
summary, the four elements include: 
 Supply network structure 
Network tier structure and shape, composition, ownership, levels of vertical 
and horizontal integration, location, co-ordination, manufacturing processes, 
optimum sequence, complexity, flexibility, etc. 
 Material and Information Flow 
Both intra- and inter-key unit operations; value and non- value adding 
activities, process steps, optimum sequence, levels of flexibility, network 
dynamics (e.g. replenishment modes), infrastructure, and enabling IT systems 
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 Relationships and Governance 
The role, inter-relationships, and governance between key network partners; 
the nature of these interactions or transactions, number, complexity, partner 
roles, governance and trust 
 Product/Service value-structure 
Product composition and structure (including components, sub-assembly, 
platforms, modularity), product replenishment mode (e.g. is the product make-
to-stock, make-to-order, configure-to-order), SKUs, products as spares, and 
through-life support and services 
Exemplars from other sectors (non-Pharma) who have reconfigured manufacturing 
operations to support more dynamic supply models are currently being investigated using 
this approach (Harrington et al. 2013, Srai and Harrington 2013). In addition, this research 
approach may also be used to describe the linkage between technology platforms and final 
product innovations (limited attention is currently paid to the industrial system that 
‘connects’ technology developments to final products e.g. changing industrial system with 
a shift from batch to CM). 
Figure 3 summarizes the industrial value chain road mapping approach, and how it 
may be reconfigured to provide a linkage between technologies and technology options to 
product iterations. It runs orthogonal to standard technology or product roadmaps and 
may identify the industrial challenges in reconfiguring the industrial chain to new and 
emerging industries e.g. (a) Mapping the Industrial Value Chain i.e. Pharma sector or for 
a specific organization/network (b) Current state Supply Network Configuration Analysis 
and (c) Re-Configuration Process (i.e. supporting ‘evolving’ Future state Value Chain, 
‘V1’ to ‘V2’ and ‘T1 Batch’ to ‘T2 CM’ implications). 
 
Figure 3. An Emerging Value Chain road mapping approach: Conceptual Framework linking  
technology evolution, network configuration and product evolution 
0 
• 
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Development of an emerging analysis framework 
Figure 4 presents a conceptualization of the Volume-Variety matrix as a means of 
representing potential areas (e.g. low volume for niche products, high volumes) where the 
benefits of CM may out-weight those of batch processing e.g. in terms of cost, providing 
beyond-OTIF profitably, reliably and sustainably. 
Low Volume? High 
Figure 4. Conceptualization of a Volume-Variety matrix: Batch v. CM 
In the development of an analysis framework (currently at the conceptual stage), it is 
proposed to identify potential ‘sub-systems’ in order to examine different and competing 
opportunities to influence/add value, e.g. 
 Therapy or Disease v Patient population? 
 Clinical trials: £ v. t 
 Primary/Secondary Processing: Quality/Yield v. Inventory? 
 Packaging: Volume v. Variety? 
 E2E: Inventory vs. Service? 
 Examine unit level critical features, critical operational metrics that may be targeted 
 Examine the linkages between the identified sub-systems 
 Explore the opportunities for disruptive supply chain models 
Conclusions 
On-going new technology development in the area of ‘Continuous Manufacturing’ (CM) 
has enabled potential for significant step changes within the Pharmaceutical sector e.g. 
shifting from traditional ‘batch’ to ‘continuous’ processing has implications for (a) 
product variety, consistency and functionality (b) energy and resource efficiency (c) 
inventory and customization options and (d) overall industry structure. This specific 
research paper looks to explore and address the operations and supply chain management 
challenges associated with CM through the development of the following approaches: 
 Exploration of the barriers and enablers for CM adoption within pharma 
 Developing an emerging Value Chain Road mapping approach: exploring product-
process archetypes and the implications new product and technology roadmaps, 
within CM and Pharma, may have on the future pharma value chain 
 Development of an emerging analysis framework; to enable end-to-end supply 
chain assessment and support overall business impact analysis in making a shift to 
CM where applicable (currently at conceptual level). 
Exemplars from other sectors (non-Pharma) who have reconfigured manufacturing 
operations to support more dynamic supply models are currently being investigated using 
emerging Value Chain Road mapping approach. These studies will look to feed into 
development of an emerging analysis framework for Pharma (currently at the conceptual 
level); to enable end-to-end supply chain assessment and support overall impact analysis 
in making the business case for CM. 
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